← Leaderboards
Jessie Villanueva
Wistar Institute
$8,602,569
Attributed
$8,602,569
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.1M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,742,602 · 9
By mechanism
R01$4,885,763 · 2
U54$4,488,556 · 3
P30$1,182,782 · 1
K01$753,990 · 1
P50$431,511 · 2
Top collaborators
- Michael Davies3 shared
- Meenhard Herlyn3 shared
Most similar at Wistar Institute
Same institution · by research overlap
- Emmanuel Skordalakes$4,027,547
- Chunling Yi$5,757,665
- Marie Ruth Webster$972,782
- Paul M. Lieberman$46,496,044
- Vito William Rebecca$2,085,689
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaDesignTumorDrug ResistanceBraf GeneMutationMutantResponseResistanceResearch PersonnelProgramsMolecularTargeted TreatmentFosteringResourcesMeksIncidenceImproved OutcomePreventMitogen-Activated Protein Kinase InhibitorMalignant NeoplasmsPre-ClinicalImmunotherapyPathway Interactions
Grant awards (36)
Rational Approaches to Melanoma Therapy$1,284,372
U54 · FY2025 · CA · contact PI
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma$977,758
R01 · FY2025 · CA · contact PI
Functional precision approaches to overcome intrinsic and acquired drug resistance in melanoma$368,862
U54 · FY2025 · CA · contact PI
Animal Shared Resource$233,258
P30 · FY2025 · CA · contact PI
Administrative Core$135,630
U54 · FY2025 · CA · contact PI
Career Enhancement Program$89,291
P50 · FY2025 · CA · contact PI
Rational Approaches to Melanoma Therapy$1,220,153
U54 · FY2024 · CA · contact PI
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma$464,112
R01 · FY2024 · CA · contact PI
Functional precision approaches to overcome intrinsic and acquired drug resistance in melanoma$380,225
U54 · FY2024 · CA · contact PI
Administrative Core$128,849
U54 · FY2024 · CA · contact PI
Career Enhancement Program$85,718
P50 · FY2024 · CA · contact PI
Rational Approaches to Melanoma Therapy$635,508
U54 · FY2023 · CA · contact PI
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma$475,922
R01 · FY2023 · CA · contact PI
Functional precision approaches to overcome intrinsic and acquired drug resistance in melanoma$255,750
U54 · FY2023 · CA · contact PI
Animal Shared Resource$241,696
P30 · FY2023 · CA · contact PI
Career Enhancement Program$83,039
P50 · FY2023 · CA · contact PI
Administrative Core$79,207
U54 · FY2023 · CA · contact PI
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma$522,753
R01 · FY2022 · CA · contact PI
Animal Shared Resource$241,696
P30 · FY2022 · CA · contact PI
Career Enhancement Program$88,354
P50 · FY2022 · CA · contact PI
Targeting TERT in Melanoma$464,587
R01 · FY2021 · CA · contact PI
Animal Shared Resource$241,696
P30 · FY2021 · CA · contact PI
Career Enhancement Program$85,109
P50 · FY2021 · CA · contact PI
Targeting TERT in Melanoma$470,176
R01 · FY2020 · CA · contact PI
Animal Shared Resource$224,436
P30 · FY2020 · CA · contact PI
Targeting TERT in Melanoma$49,013
R01 · FY2020 · CA · contact PI
Targeting TERT in Melanoma$426,277
R01 · FY2019 · CA · contact PI
Targeting TERT in Melanoma$92,585
R01 · FY2019 · CA · contact PI
Targeting TERT in Melanoma$439,320
R01 · FY2018 · CA · contact PI
Targeting TERT in Melanoma$64,077
R01 · FY2018 · CA · contact PI
Targeting TERT in Melanoma$439,183
R01 · FY2017 · CA · contact PI
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan$150,798
K01 · FY2017 · CA · contact PI
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan$150,798
K01 · FY2016 · CA · contact PI
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan$150,798
K01 · FY2015 · CA · contact PI
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan$150,798
K01 · FY2014 · CA · contact PI
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan$150,798
K01 · FY2013 · CA · contact PI